MHRA

Hemp plants being used in scientific research
#Chronic pain #MHRA #THC #UK

UK approval for CBD pain treatment

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a CBD/THC combination treatment under its Named Patient programme and other compassionate areas. Medlab’s NanaBis, to be used under NanaDol, a botanical version of NanaBis, has previously shown encouraging Phase I/II data for the treatment of cancer-induced bone pain… Read More

#News #Regulatory #Trending News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

News update available on DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  Gene therapies have made the headlines over the last week, with treatments… Read More

#News

#Cancer research #Diabetes #Drug development #Drug discovery #FDA #Gene therapy #Haemophilia #MHRA #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders

This week in drug discovery (21-25 November)

News round-up for 21-25 November by DDW Digital Content Editor Diana Spencer  Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. This week has also seen the first… Read More

#News

Child having physiotherapy
#Gene therapy #MHRA #Rare disease #UK

Gene therapy could ‘transform prognosis’ for AADC deficiency patients 

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) has received authorisation from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK.   Upstaza is the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency. It is also the first marketed gene therapy directly infused into the brain. The MHRA marketing… Read More

#News #Regulatory

Child having ultrasound on knee
#Arthritis #Juvenile idiopathic arthritis #MHRA #Novartis #Paediatrics #Phase III trial

UK MHRA expands Cosentyx use in paediatric arthritic conditions

The UK Medicines & Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for Novartis’ Cosentyx (secukinumab) in two types of juvenile idiopathic arthritis (JIA), enthesitis-related arthritis (ERA), and juvenile psoriatic arthritis (JPsA).  The drug is approved alone or in combination with methotrexate (MTX) in… Read More

#News

MHRA
#AAV #Geographic atrophy #MHRA #Therapeutics

Green light for potential AAV gene therapy 

Complement Therapeutics’ lead asset CTx001, an AAV-based gene therapy for the treatment of geographic atrophy (GA), has been awarded an Innovation Passport by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA).  CTx001 was awarded the Innovation Passport based on three criteria: that the condition addressed is seriously debilitating with… Read More

#News #Regulatory

Preparing Covid-19 vaccine for injection
#Covid booster #Covid-19 #Covid-19 vaccine #MHRA #Phase III trial #Vaxxinity

New class of Covid-19 booster completes enrollment of Phase III trial

Global Phase III topline data is expected later this year for a new class of Covid-19 booster vaccine. Vaxxinity has completed enrollment for the trial, co-sponsored by the Coalition for Epidemic Preparedness Innovations (CEPI). Its UB-612 will be evaluated as a heterologous booster vaccine to mRNA, adeno-vectored, and inactivated primary… Read More

#Covid-19 #Editor's Choice #News

Girl testing blood glucose levels
#Diabetes #MHRA #Type 2 diabetes

New class of treatment approved for diabetic patients in the UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new class of treatment for adults with insufficiently controlled type 2 diabetes.  Marketing authorisation has been granted for Eli Lilly’s tirzepatide (Mounjaro), a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1… Read More

#News

Child with insomnia
#ADHD #Insomnia #MHRA #Sleep onset insomnia

MHRA approves ADHD treatment for children with insomnia

The MHRA has approved Colonis’ Melatonin 1mg/ml Oral Solution for sleep onset insomnia in children and adolescents aged 6-17 years with attention-deficit hyperactivity disorder (ADHD), where sleep hygiene measures have been inadequate. Clinical evidence demonstrates that Melatonin has the potential to decrease sleep latency and increase sleep efficiency in children… Read More

#News #Regulatory

Alopecia
#Alopecia #Dermatology #Hair loss #JAK inhibitor #MHRA

First oral therapy for severe alopecia areata approved in UK

The MHRA has granted marketing authorisation for Eli Lilly’s baricitinib (Olumiant), the first licensed JAK inhibitor for the treatment of severe alopecia areata in adult patients.   The authorisation was based on BRAVE-AA1 and BRAVE-AA2 studies which both met the primary endpoint of the proportion of patients achieving SALT ≤20 (i.e.,… Read More

#News #Regulatory

#Appointment #Covid-19 #EMA #MHRA #Oncology

This week in drug discovery (15-19 August)

News round-up by DDW Editor Reece Armstrong for 15-19 August. Covid booster approvals, positive results for Malaria vaccines and new CEOs are some of the stories in this week’s news round-up.  MHRA approves Moderna’s bivalent Covid booster   The Medicines and Healthcare products Regulatory Agency (MHRA) has approved an updated… Read More

#News

Stamp of approval
#Drug approvals #MHRA #Novartis #Oncology

MHRA approves Novartis treatment for CML  

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted Marketing Authorisation to Novartis UK’s treatment for a specific type of cancer.  The authorisation was granted for Scemblix (asciminib), Novartis UK’s therapy for adults with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) who have previously been treated… Read More

#News #Regulatory

#MHRA #Regulatory

MHRA increases global standing through international partnerships  

The Medicines and Healthcare products Regulatory Agency (MHRA) has partnered with three international organisations to bolster its position on setting standards for medicines and medical devices.    The MHRA has been accepted as a full member of the International Medical Device Regulatory Forum (IMDRF), the International Council for Harmonisation of… Read More

#News

#Eli Lilly #MHRA #Oncology #Regulatory

MHRA approves Eli Lilly’s breast cancer oral inhibitor  

The Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation to Eli Lilly’s oral inhibitor abemaciclib for the treatment of patients with a specific type of breast cancer.   Abemaciclib will now be able to be used in combination with endocrine therapy for the adjuvant treatment… Read More

#News

#Biologics / Biotechnology #Hearing Loss #MHRA

Rinri Therapeutics awarded for hearing loss therapy  

Biotechnology company Rinri Therapeutics has been awarded an Innovation Passport by the UK Medicines and Healthcare products Regulatory Agency’s (MHRA) for its cell therapy targeting a form of hearing loss.  The Innovation Passport, which is awarded through the MHRA’s Innovative Licensing and Access Pathway (ILAP), will enable… Read More

#News